In-Situ Generated Polymeric Devices for the Treatment of Aortic Abdominal Aneurysms (AAA)

Cohn Daniel, HUJI, Faculty of Science, The Institute of Chemistry



The rupture of the aneurysmal sac, typically results in almost immediate death, with the burst of Aortic Abdominal Aneurysms (AAA) ranking as the 13th cause of mortality in the U.S.

 The stent can be inserted with minimally invasive procedures:

  • Isolation of the weak aneurysmal arterial wall from the aortic blood stream, immediately minimizing the risk of life-threatening hemorrhage due to sudden rupture
  • Restoration of the artery's luminal cylindrical geometry, distorted by the aneurysmal expansion.


The polymers used to make the stents and their properties and the method of expanding and sealing the polymer tube to the aorta.

Key Features

This minimally invasive surgical procedure protects an aortic aneurysm from rupture while restoring the aorta’s cylindrical geometry. It uses a thermo-expandable polymer tube (stent) that can be inserted into the aorta, and then subsequently expanded to allow the tube to tightly attach to the vessel, proximally and distally to the aneurysm so that it may isolate the aneurysmal arterial wall from the aortic blood stream. It has no interfaces that can cause endoleaks and provides a significantly lower cost alternative to typical endovascular aortic repair.

Development Milestones

Current Development Stage: Technology Readiness Level (TRL) = 6; i.e., System/subsystem model or prototype demonstrated in a relevant environment. Continued in vivo animal and human studies are needed to obtain regulatory approval unless substantial equivalence with approved devices can be shown.

The Opportunity

The formation of aneurysms is an extremely dangerous degenerative pathology of arterial tissues, especially common in adult and elderly populations, whereby the wall of the artery weakens locally and markedly expands. With an aging population in many nations, the market opportunity will only grow. This invention could cut healthcare costs while improving patient outcomes. The technology may also be useful for other analogous maladies.




Patent Status

Granted US 9,526,813

Contact for more information:

Mel Larrosa
VP Business Development Healthcare
Contact ME: